DGAM
RPRX icon

Desjardins Global Asset Management’s Royalty Pharma RPRX Stock Holding History

Desjardins Global Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$63.7K Buy
2,266
+31
+1% +$852 0.01% 507
2023
Q3 		$60.7K Buy
+2,235
New +$66.4K 0.01% 519

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Desjardins Global Asset Management's RPRX Position: Q4 2023 in Review

Desjardins Global Asset Management increased its Royalty Pharma (RPRX) stake by 1.4% in Q4 2023, buying an estimated $852 and bringing the position to 2,266 shares worth $63.7K. The position accounts for 0.01% of the portfolio, ranked #507.

Desjardins Global Asset Management first reported a position in RPRX in Q3 2023 and has held it in 2 quarters since. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

  • Desjardins Global Asset Management held 2,266 shares of Royalty Pharma worth $63.7K as of Q4 2023.
  • Desjardins Global Asset Management bought 31 Royalty Pharma shares in Q4 2023, an estimated $852.
  • Royalty Pharma made up 0.01% of Desjardins Global Asset Management's portfolio in Q4 2023, its #507 holding.
  • Desjardins Global Asset Management first reported a position in Royalty Pharma in Q3 2023 and has held it in 2 quarters since.
  • 363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.